All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of myocardial infarction (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of suspected serious drug reactions (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Fracture · preventing bone disease in kidney transplant recipients
Bisphosphonate showed no clear difference in fracture compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (all causes) · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes death (all causes) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular mortality · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes cardiovascular death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Graft loss · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes graft loss compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Acute rejection · preventing bone disease in kidney transplant recipients
Bisphosphonate may leads to lower acute graft rejection compared with placebo or no treatment (low certainty).
1 finding from 1 review
Death (all causes) · preventing bone disease in kidney transplant recipients
It is very uncertain whether bisphosphonate changes death (all causes) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular mortality · preventing bone disease in kidney transplant recipients
It is very uncertain whether bisphosphonate changes cardiovascular death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Spinal deformity · preventing bone disease in kidney transplant recipients
It is very uncertain whether bisphosphonate changes spinal deformity compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Hypocalcaemia · preventing bone disease in kidney transplant recipients
It is very uncertain whether bisphosphonate changes hypocalcaemia compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Fracture · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes fracture compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Acute rejection · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes acute graft rejection compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Intervention not reported
T1 maternal mental health CES‐D (mean score)a · lone parents
1 finding from 1 review